Liposome: Difference between revisions
Brian Blank (talk | contribs) No edit summary |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 1: | Line 1: | ||
[[Image:Liposome.jpg|thumb|right|250px|Liposomes are polymeric nanoparticles with various targeting ligands attached to their surface allowing for their surface-attachment and accumulation in pathological areas for treatment of disease<ref> Torchilin VP. (2006)Adv Drug Deliv Rev. 2006 Dec 1;58(14):1532-55</ref>.]] | [[Image:Liposome.jpg|thumb|right|250px|Liposomes are polymeric nanoparticles with various targeting ligands attached to their surface allowing for their surface-attachment and accumulation in pathological areas for treatment of disease<ref> Torchilin VP. (2006)Adv Drug Deliv Rev. 2006 Dec 1;58(14):1532-55</ref>.]] | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
| Line 42: | Line 42: | ||
[[Category:Membrane biology]] | [[Category:Membrane biology]] | ||
[[de:Liposom]] | [[de:Liposom]] | ||
[[es:Liposoma]] | [[es:Liposoma]] | ||
Latest revision as of 16:54, 9 August 2012
|
WikiDoc Resources for Liposome |
|
Articles |
|---|
|
Most recent articles on Liposome |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Liposome at Clinical Trials.gov Clinical Trials on Liposome at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Liposome
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating Liposome Risk calculators and risk factors for Liposome
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Liposome |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
A liposome is a spherical vesicle composed of a bilayer membrane. In biology, this specifically refers to a membrane composed of a phospholipid and cholesterol bilayer (see on the right). Liposomes can be composed of naturally-derived phospholipids with mixed lipid chains (like egg phosphatidylethanolamine), or of pure surfactant components like DOPE (dioleoylphosphatidylethanolamine). Liposomes, usually but not by definition, contain a core of aqueous solution; lipid spheres that contain no aqueous material are called micelles, however, reverse micelles [1] can be made to encompass an aqueous environment.
Etymology
The name liposome is derived from two Greek words 'Lipid' meaning fat and 'Soma' meaning body. The word liposome does not in itself denote any size characteristics as is frequently presumed and therefore is not an alternative to a Nanosome. Furthermore the term liposome does not necessarily mean that it must contain lipophobic contents, such as water, although it usually does.
Discovery
Liposomes were first described by British haematologist Sir. Alec D Bangham in 1961 (published 1964), at the Babraham institute, Cambridge. They were discovered when Bangham and R. W. Horne were testing the institute's new electron microscope by adding negative stain to dry phospholipids. The resemblance to the plasmalemma was obvious, and the microscope pictures served as the first real evidence for the cell membrane being a bilayer lipid structure.
Application
Liposomes are used for drug delivery due to their unique properties. A liposome encapsulates a region on aqueous solution inside a hydrophobic membrane; dissolved hydrophilic solutes can not readily pass through the lipids. Hydrophobic chemicals can be dissolved into the membrane, and in this way liposome can carry both hydrophobic molecules and hydrophilic molecules. To deliver the molecules to sites of action, the lipid bilayer can fuse with other bilayers such as the cell membrane, thus delivering the liposome contents. By making liposomes in a solution of DNA or drugs (which would normally be unable to diffuse through the membrane) they can be (indiscriminately) delivered past the lipid bilayer.
Liposomes can also be designed to deliver drugs in other ways. Liposomes that contain low (or high) pH can be constructed such that dissolved aqueous drugs will be charged in solution (i.e., the pH is outside the drug's pI range). As the pH naturally neutralizes within the liposome (protons can pass through some membranes), the drug will also be neutralized, allowing it to freely pass through a membrane. These liposomes work to deliver drug by diffusion rather than by direct cell fusion. Another strategy for liposome drug delivery is to target endocytosis events. Liposomes can be made in a particular size range that makes them viable targets for natural macrophage phagocytosis. These liposomes may be digested while in the magrophage's phagosome, thus releasing its drug. Liposomes can also be decorated with opsonins and ligands to activate endocytosis in other cell types.
- The use of liposomes for transformation or transfection of DNA into a host cell is known as lipofection.
Targeting cancer
Another interesting property of liposomes are their natural ability to target cancer. The endothelial wall of all healthy human blood vessels are encapsulated by endothelial cells that are bound together by tight junctions. These tight junctions stop any large particle of in the blood from leaking out of the vessel. Tumour vessels do not contain the same level of seal between cells and are diagnostically leaky. This ability is known as the Enhanced Permeability and Retention effect. Liposomes of certain sizes, typically less than 400nm, can rapidly enter tumour sites from the blood, but are kept in the bloodstream by the endothelial wall in healthy tissue vasculature. Anti-cancer drugs such as Doxorubicin (Doxil) and Daunorubicin (Daunoxome) are currently being marketed in liposome delivery systems.
Manufacturing
Liposomes can be created by sonicating phospholipids in water. Low shear rates create multilamellar liposomes, which have many layers like an onion. Continued high-shear sonication tends to form smaller unilamellar liposomes. In this technique, the liposome contents are the same as the contents of the aqueous phase. Sonication is generally considered a "gross" method of preparation, and newer methods such as extrusion are employed to produce materials for human use.
Prospect
Further advances in liposome research have been able to allow liposomes to avoid detection by the body's immune system, specifically, the cells of reticuloendothelial system (RES). These liposomes are known as "stealth liposomes", and are constructed with PEG (Polyethylene Glycol) studding the outside of the membrane. The PEG coating, which is inert in the body, allows for longer circulatory life for the drug delivery mechanism. However, research currently seeks to investigate at what amount of PEG coating the PEG actually hinders binding of the liposome to the delivery site. In addition to a PEG coating, most stealth liposomes also have some sort of biological species attached as a ligand to the liposome in order to enable binding via a specific expression on the targeted drug delivery site. These targeting ligands could be monoclonal antibodies (making an immunoliposome), vitamins, or specific antigens. Targeted liposomes can target nearly any cell type in the body and deliver drugs that would naturally be systemically delivered. Naturally toxic drugs can be much less toxic if delivered only to diseased tissues.
References
- ↑ Torchilin VP. (2006)Adv Drug Deliv Rev. 2006 Dec 1;58(14):1532-55